SG3 Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SG3 Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$517K	–	37
2022 Q4	$517K	Buy	5,000 +4,100	+456%	+$385K	0.07%	115
2022 Q3	$76.3K	Buy	+900	New	+$80.1K	0.01%	237
2022 Q2	–	Sell	-70,000	Closed	-$5.4M	–	458
2022 Q1	$5.4M	Buy	70,000 +4,100	+6%	+$343K	0.15%	135
2021 Q4	$5.82M	Buy	65,900 +14,600	+28%	+$1.2M	0.12%	150
2021 Q3	$3.96M	Buy	51,300 +17,600	+52%	+$1.39M	0.12%	171
2021 Q2	$2.81M	Sell	33,700 -41,400	-55%	-$3.28M	0.1%	235
2021 Q1	$5.67M	Sell	75,100 -101,900	-58%	-$8.32M	0.14%	155
2020 Q4	$15.5M	Buy	177,000 +162,000	+1,080%	+$12.8M	0.3%	69
2020 Q3	$1.14M	Buy	15,000 +200	+1%	+$20.2K	0.04%	398
2020 Q2	$1.82M	Buy	+14,800	New	+$1.47M	0.13%	208
2018 Q3	–	Sell	-15,000	Closed	-$1.41M	–	153
2018 Q2	$1.41M	Buy	+15,000	New	+$1.31M	0.32%	48

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG3 Management's BMRN Position: Q1 2023 in Review

SG3 Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,500 shares — an estimated $259K sold.

SG3 Management first reported a position in BMRN in Q4 2020 and held it in 8 quarters. The position peaked at $3.15M in Q4 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

SG3 Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 2,500 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $259K.
SG3 Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 8 quarters.
SG3 Management's BioMarin Pharmaceuticals position peaked at $3.15M in Q4 2020.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.